X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs GSK PHARMA - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS GSK PHARMA IPCA LABS/
GSK PHARMA
 
P/E (TTM) x 36.4 66.9 54.4% View Chart
P/BV x 3.5 11.7 29.5% View Chart
Dividend Yield % 0.1 1.1 13.8%  

Financials

 IPCA LABS   GSK PHARMA
EQUITY SHARE DATA
    IPCA LABS
Mar-17
GSK PHARMA
Mar-17
IPCA LABS/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs6433,838 16.8%   
Low Rs5032,637 19.1%   
Sales per share (Unadj.) Rs254.4354.2 71.8%  
Earnings per share (Unadj.) Rs16.139.8 40.4%  
Cash flow per share (Unadj.) Rs29.842.9 69.5%  
Dividends per share (Unadj.) Rs1.0030.00 3.3%  
Dividend yield (eoy) %0.20.9 18.8%  
Book value per share (Unadj.) Rs194.6236.9 82.1%  
Shares outstanding (eoy) m126.2084.70 149.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.39.1 24.6%   
Avg P/E ratio x35.781.4 43.8%  
P/CF ratio (eoy) x19.275.5 25.5%  
Price / Book Value ratio x2.913.7 21.6%  
Dividend payout %6.275.4 8.2%   
Avg Mkt Cap Rs m72,300274,216 26.4%   
No. of employees `00013.34.7 283.2%   
Total wages/salary Rs m6,9604,830 144.1%   
Avg. sales/employee Rs Th2,413.56,387.0 37.8%   
Avg. wages/employee Rs Th523.21,028.3 50.9%   
Avg. net profit/employee Rs Th152.4717.1 21.3%   
INCOME DATA
Net Sales Rs m32,10630,000 107.0%  
Other income Rs m226728 31.0%   
Total revenues Rs m32,33230,728 105.2%   
Gross profit Rs m4,4484,190 106.2%  
Depreciation Rs m1,730263 657.6%   
Interest Rs m2410-   
Profit before tax Rs m2,7034,655 58.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0457 0.0%   
Tax Rs m6751,744 38.7%   
Profit after tax Rs m2,0283,368 60.2%  
Gross profit margin %13.914.0 99.2%  
Effective tax rate %25.037.5 66.7%   
Net profit margin %6.311.2 56.3%  
BALANCE SHEET DATA
Current assets Rs m17,34016,742 103.6%   
Current liabilities Rs m9,5597,202 132.7%   
Net working cap to sales %24.231.8 76.2%  
Current ratio x1.82.3 78.0%  
Inventory Days Days10052 193.6%  
Debtors Days Days5721 273.6%  
Net fixed assets Rs m20,7798,635 240.6%   
Share capital Rs m252847 29.8%   
"Free" reserves Rs m24,49919,222 127.5%   
Net worth Rs m24,55320,069 122.3%   
Long term debt Rs m3,51710 35,174.0%   
Total assets Rs m39,59530,038 131.8%  
Interest coverage x12.2NM-  
Debt to equity ratio x0.10 28,750.2%  
Sales to assets ratio x0.81.0 81.2%   
Return on assets %5.711.2 51.1%  
Return on equity %8.316.8 49.2%  
Return on capital %10.525.5 41.2%  
Exports to sales %48.60-   
Imports to sales %14.20-   
Exports (fob) Rs m15,617NA-   
Imports (cif) Rs m4,571NA-   
Fx inflow Rs m15,617528 2,957.8%   
Fx outflow Rs m5,8287,193 81.0%   
Net fx Rs m9,790-6,665 -146.9%   
CASH FLOW
From Operations Rs m2,7642,360 117.1%  
From Investments Rs m-1,4323,008 -47.6%  
From Financial Activity Rs m-1,591-5,108 31.2%  
Net Cashflow Rs m-259260 -99.4%  

Share Holding

Indian Promoters % 45.9 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 11.4 10.2 111.8%  
FIIs % 25.3 23.8 106.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 15.4 113.0%  
Shareholders   36,892 102,036 36.2%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   AJANTA PHARMA  GLENMARK PHARMA  AUROBINDO PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  

Compare IPCA LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Volatile Day in Red; Pharma Stocks Lose Most(Closing)

After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day on a negative note.

Related Views on News

IPCA LABS Announces Quarterly Results (4QFY18); Net Profit Up 15.6%

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, IPCA LABS has posted a net profit of Rs 513 m (up 15.6% YoY). Sales on the other hand came in at Rs 8 bn (up 17.6% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

GSK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.4%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 6.4% YoY). Sales on the other hand came in at Rs 7 bn (down 4.5% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Jun 21, 2018 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE IPCA LABS WITH

MARKET STATS